U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C20H28O2
Molecular Weight 300.4351
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 4
Charge 0

SHOW SMILES / InChI
Structure of Tretinoin

SMILES

CC(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(C)=C/C(O)=O

InChI

InChIKey=SHGAZHPCJJPHSC-YCNIQYBTSA-N
InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+

HIDE SMILES / InChI

Molecular Formula C20H28O2
Molecular Weight 300.4351
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 4
Optical Activity NONE

Description

Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid indicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro. Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. In the United States, topical alitretinoin (in the form of a gel; trade name Panretin) is indicated for the treatment of skin lesions in AIDS-related Kaposi's sarcoma.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ACCUTANE

Approved Use

Accutane is indicated for the treatment of severe recalcitrant nodular acne. Nodules are inflammatory lesions with a diameter of 5 mm or greater. The nodules may become suppurative or hemorrhagic. “Severe,” by definition, means “many” as opposed to “few or several” nodules. Because of significant adverse effects associated with its use, Accutane should be reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. In addition, Accutane is indicated only for those female patients who are not pregnant, because Accutane can cause severe birth defects.

Launch Date

1982
Primary
RETIN-A

Approved Use

RETIN-A is indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the long-term use of this product in the treatment of other disorders have not been established.

Launch Date

1971
Palliative
TRETINOIN

Approved Use

retinoin Capsules are indicated for the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant), characterized by the presence of the t(15;17) translocation and/or the presence of the PML/RARα gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline based chemotherapy is contraindicated. Tretinoin is for the induction of remission only. The optimal consolidation or maintenance regimens have not been defined, but all patients should receive an accepted form of remission consolidation and/or maintenance therapy for APL after completion of induction therapy with tretinoin.

Launch Date

2007
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
314 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOTRETINOIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4055 ng × h/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOTRETINOIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
24 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOTRETINOIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.1%
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOTRETINOIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
12.5 mg/kg single, oral
Overdose
Dose: 12.5 mg/kg
Route: oral
Route: single
Dose: 12.5 mg/kg
Sources:
unhealthy, 29
Health Status: unhealthy
Age Group: 29
Sex: M
Sources:
Disc. AE: Cheilitis, Skin xerosis...
AEs leading to
discontinuation/dose reduction:
Cheilitis
Skin xerosis
Desquamation
Headache
Skin xerosis
Sources:
1000 mg single, oral
Overdose
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources:
unhealthy, 31
Health Status: unhealthy
Age Group: 31
Sex: M
Sources:
Disc. AE: Diarrhea...
AEs leading to
discontinuation/dose reduction:
Diarrhea
Sources:
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources:
unhealthy, 4
Health Status: unhealthy
Age Group: 4
Sex: M+F
Sources:
DLT: Hypercalcemia, Skin toxicity...
Dose limiting toxicities:
Hypercalcemia (grade 4, 22.2%)
Skin toxicity (grade 3, 33.3%)
Anemia (grade 3, 11.1%)
Thrombocytopenia (grade 3, 11.1%)
Emesis (grade 3, 11.1%)
Hypercalcemia (grade 3, 11.1%)
Sources:
80 mg/m2 2 times / day multiple, oral
MTD
Dose: 80 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg/m2, 2 times / day
Sources:
unhealthy, 4
Health Status: unhealthy
Age Group: 4
Sex: M+F
Sources:
DLT: Hypercalcemia, Skin toxicity...
Dose limiting toxicities:
Hypercalcemia (grade 4, 4.3%)
Skin toxicity (grade 3, 17.4%)
Emesis (grade 3, 4.3%)
AST/ALT ratio abnormal (grade 3, 4.3%)
Sources:
80 mg/m2 2 times / day multiple, oral
MTD
Dose: 80 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg/m2, 2 times / day
Sources:
unhealthy, 4
Health Status: unhealthy
Age Group: 4
Sex: M+F
Sources:
1 mg/kg 2 times / day multiple, oral
Recommended
Dose: 1 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 1 mg/kg, 2 times / day
Sources:
unhealthy
Disc. AE: Fetal damage...
AEs leading to
discontinuation/dose reduction:
Fetal damage (grade 4)
Sources:
AEs

AEs

AESignificanceDosePopulation
Cheilitis Disc. AE
12.5 mg/kg single, oral
Overdose
Dose: 12.5 mg/kg
Route: oral
Route: single
Dose: 12.5 mg/kg
Sources:
unhealthy, 29
Health Status: unhealthy
Age Group: 29
Sex: M
Sources:
Desquamation Disc. AE
12.5 mg/kg single, oral
Overdose
Dose: 12.5 mg/kg
Route: oral
Route: single
Dose: 12.5 mg/kg
Sources:
unhealthy, 29
Health Status: unhealthy
Age Group: 29
Sex: M
Sources:
Headache Disc. AE
12.5 mg/kg single, oral
Overdose
Dose: 12.5 mg/kg
Route: oral
Route: single
Dose: 12.5 mg/kg
Sources:
unhealthy, 29
Health Status: unhealthy
Age Group: 29
Sex: M
Sources:
Skin xerosis Disc. AE
12.5 mg/kg single, oral
Overdose
Dose: 12.5 mg/kg
Route: oral
Route: single
Dose: 12.5 mg/kg
Sources:
unhealthy, 29
Health Status: unhealthy
Age Group: 29
Sex: M
Sources:
Skin xerosis Disc. AE
12.5 mg/kg single, oral
Overdose
Dose: 12.5 mg/kg
Route: oral
Route: single
Dose: 12.5 mg/kg
Sources:
unhealthy, 29
Health Status: unhealthy
Age Group: 29
Sex: M
Sources:
Diarrhea Disc. AE
1000 mg single, oral
Overdose
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources:
unhealthy, 31
Health Status: unhealthy
Age Group: 31
Sex: M
Sources:
Anemia grade 3, 11.1%
DLT
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources:
unhealthy, 4
Health Status: unhealthy
Age Group: 4
Sex: M+F
Sources:
Emesis grade 3, 11.1%
DLT
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources:
unhealthy, 4
Health Status: unhealthy
Age Group: 4
Sex: M+F
Sources:
Hypercalcemia grade 3, 11.1%
DLT
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources:
unhealthy, 4
Health Status: unhealthy
Age Group: 4
Sex: M+F
Sources:
Thrombocytopenia grade 3, 11.1%
DLT
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources:
unhealthy, 4
Health Status: unhealthy
Age Group: 4
Sex: M+F
Sources:
Skin toxicity grade 3, 33.3%
DLT
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources:
unhealthy, 4
Health Status: unhealthy
Age Group: 4
Sex: M+F
Sources:
Hypercalcemia grade 4, 22.2%
DLT
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources:
unhealthy, 4
Health Status: unhealthy
Age Group: 4
Sex: M+F
Sources:
Skin toxicity grade 3, 17.4%
DLT
80 mg/m2 2 times / day multiple, oral
MTD
Dose: 80 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg/m2, 2 times / day
Sources:
unhealthy, 4
Health Status: unhealthy
Age Group: 4
Sex: M+F
Sources:
AST/ALT ratio abnormal grade 3, 4.3%
DLT
80 mg/m2 2 times / day multiple, oral
MTD
Dose: 80 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg/m2, 2 times / day
Sources:
unhealthy, 4
Health Status: unhealthy
Age Group: 4
Sex: M+F
Sources:
Emesis grade 3, 4.3%
DLT
80 mg/m2 2 times / day multiple, oral
MTD
Dose: 80 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg/m2, 2 times / day
Sources:
unhealthy, 4
Health Status: unhealthy
Age Group: 4
Sex: M+F
Sources:
Hypercalcemia grade 4, 4.3%
DLT
80 mg/m2 2 times / day multiple, oral
MTD
Dose: 80 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg/m2, 2 times / day
Sources:
unhealthy, 4
Health Status: unhealthy
Age Group: 4
Sex: M+F
Sources:
Fetal damage grade 4
Disc. AE
1 mg/kg 2 times / day multiple, oral
Recommended
Dose: 1 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 1 mg/kg, 2 times / day
Sources:
unhealthy
Overview

Overview

Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
minor
minor
minor
minor
minor
no
no
no
no
no
no
no
yes
yes
yes
yes
yes
PubMed

PubMed

TitleDatePubMed
[Tissue factor expression during all-trans retinoic acid or arsenic trioxide treatment in acute promyelocytic leukemia].
1998 Sep
All-trans retinoic acid-induced vasculitis and hemonecrosis of the ileum in a patient with acute promyelocytic leukemia.
1999 Apr
All-trans retinoic acid-induced multiple mononeuropathies.
1999 Apr
Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
1999 Dec
Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents.
1999 Jul
HMGI(Y) and HMGI-C genes are expressed in neuroblastoma cell lines and tumors and affect retinoic acid responsiveness.
1999 May 15
[Effects of all-trans retinoic acid, arsenic trioxide and daunorubicin on tissue factor expression in NB4 cells].
1999 Sep
Pseudotumor cerebri induced by all-trans-retinoic acid in a child treated for acute promyelocytic leukemia.
2000 Apr
All trans retinoic acid induces apoptosis in acute promyelocytic NB4 cells when combined with isoquinolinediol, a poly(ADP-ribose) polymerase inhibitor.
2000 Apr
Effect of retinoic acid on the enhancing effect of acetaldehyde on mouse type I collagen expression.
2000 Apr 1
2,3,7,8-tetrachlorodibenzo-p-dioxin increases serum and kidney retinoic acid levels and kidney retinol esterification in the rat.
2000 Dec 1
Chelation of zinc amplifies induction of growth hormone mRNA levels in cultured rat pituitary tumor cells.
2000 Feb
Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia.
2000 Feb
All-trans-retinoic acid-induced myositis: a description of two patients.
2000 Feb
The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution.
2000 Jan
Transcriptional induction of Nur77 by indomethacin that results in apoptosis of colon cancer cells.
2000 Jul
Regulation of retinoic acid signaling during lung morphogenesis.
2000 Jul
Pathways through which a regimen of melatonin and retinoic acid induces apoptosis in MCF-7 human breast cancer cells.
2000 Jun
Fatty acid binding proteins from different tissues show distinct patterns of fatty acid interactions.
2000 Jun 20
[Severe side effects of the treatment of acute promyelocytic leukemia with all-trans retinoic acid].
2000 Jun 28
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes.
2000 Mar
Differential regulation of apoptosis in normal versus transformed mammary epithelium by lutein and retinoic acid.
2000 Mar
Phase I trial of all-trans retinoic acid in patients with treated head and neck squamous carcinoma.
2000 Mar
Thrombosis during all-trans-retinoic acid therapy in a child with acute promyelocytic leukemia and factor VQ 506 mutation.
2000 Mar
[Mechanism of tissue factor expression on NB4 cells down-regulated by all-trans retinoic acid and arsenic trioxide].
2000 May
Acute hepatomegaly with severe liver toxicity due to all-trans-retinoic acid.
2000 May
Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients.
2000 Nov
Regulation of aquaporin-4 expression in astrocytes.
2001 Apr 18
Carnosic acid and promotion of monocytic differentiation of HL60-G cells initiated by other agents.
2001 Aug 15
Retinoic acid-mediated growth arrest requires ubiquitylation and degradation of the F-box protein Skp2.
2001 Dec 7
Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo.
2001 Jan 1
Analysis of cartilage-derived retinoic acid-sensitive protein in cerebrospinal fluid From patients With spinal diseases.
2001 Jan 15
Regulation of IL-5 receptor on eosinophil progenitors in allergic inflammation: role of retinoic acid.
2001 Jan-Mar
Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL.
2001 Jun
Short heterodimer partner (SHP) orphan nuclear receptor inhibits the transcriptional activity of aryl hydrocarbon receptor (AHR)/AHR nuclear translocator (ARNT).
2001 Jun 1
Expression of retinoic acid receptor gamma correlates with retinoic acid sensitivity and metabolism in head and neck squamous cell carcinoma cell lines.
2001 Jun 1
Characterization of a novel airway epithelial cell-specific short chain alcohol dehydrogenase/reductase gene whose expression is up-regulated by retinoids and is involved in the metabolism of retinol.
2001 Jun 29
1,25-dihydroxyvitamin D3 and retonic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects.
2001 May
Retinoic acid prevents experimental Cushing syndrome.
2001 Oct
All-trans retinoic acid inhibits vascular smooth muscle cell proliferation targeting multiple genes for cyclins and cyclin-dependent kinases.
2001 Sep
Granulomatous tubulointerstitial nephritis induced by all-trans retinoic acid.
2001 Sep
Gene-specific TCDD suppression of RARalpha- and RXR-mediated induction of tissue transglutaminase.
2002 Jul
Down-regulation of the phosphatidylinositol 3-kinase/Akt pathway is involved in retinoic acid-induced phosphorylation, degradation, and transcriptional activity of retinoic acid receptor gamma 2.
2002 Jul 12
Transient dilated cardiomyopathy in a newborn exposed to idarubicin and all-trans-retinoic acid (ATRA) early in the second trimester of pregnancy.
2002 Jul-Aug
Excentric cleavage products of beta-carotene inhibit estrogen receptor positive and negative breast tumor cell growth in vitro and inhibit activator protein-1-mediated transcriptional activation.
2002 Jun
Pathogenesis of murine experimental allergic rhinitis: a study of local and systemic consequences of IL-5 deficiency.
2002 Mar 15
[Genetic dissection of retinoic acid function in epidermis physiology].
2002 May
Analysis of cartilage-derived retinoic-acid-sensitive protein (CD-RAP) in synovial fluid from patients with osteoarthritis and rheumatoid arthritis.
2002 Sep
All-trans-retinoic acid induces CD52 expression in acute promyelocytic leukemia.
2003 Mar 1
Effects of 9-cis retinoic acid on human homeobox gene NKX3.1 expression in prostate cancer cell line LNCaP.
2006 Jul
Patents

Sample Use Guides

acute promyelocytic leukemia (APL): The recommended dose is 45 mg/m2/day administered as two evenly divided doses until complete remission is documented. Therapy should be discontinued 30 days after achievement of complete remission or after 90 days of treatment, whichever occurs first. acne vulgaris: RETIN-A Gel, Cream or Liquid should be applied once a day, before retiring, to the skin where acne lesions appear, using enough to cover the entire affected area lightly. Liquid: the liquid may be applied using a fingertip, gauze pad, or cotton swab. If gauze or cotton is employed, care should be taken not to oversaturate it, to the extent that the liquid would run into areas where treatment is not intended. Gel: Excessive application results in “pilling” of the gel, which minimizes the likelihood of over application by the patient.
Route of Administration: Other
Human bronchial SMCs were used and pretreated with or without tretinoin, also known as all-trans-retinoic acid (ATRA), (2 μM) for 20 min before the addition of PDGF (1 μg/ml), or ATRA alone. The neutral comet assay, which determines the incidence of double-stranded DNA breaks, was used to demonstrate that ATRA treatment induced apoptosis of bovine and human pulmonary artery SMC. In contrast, apoptotic cell death was not produced in response to ATRA in human bronchial airway SMC, as monitored by comet assay. Similarly, TUNEL assay and the measurement of mitochondrial membrane potential failed to demonstrate significant apoptosis by ATRA in airway SMCs. Positive controls, daunorubicin (DNR) and hydrogen peroxide, effectively elicited apoptosis in airway SMC. Because ATRA inhibited both morphologic and actin cytoskeletal changes induced by PDGF, it was characterized the effects of ATRA on PDGF-induced airway SMC migration using a modified Boyden chamber assay, which allows for determination of motility in random directions. PDGF caused a 4-fold increase in migration of airway SMCs after 24 h, and ATRA blocked these events. ATRA by itself had no effect. While the therapeutic level of ATRA in human plasma could reach 1–2 μM, the effects on airway SMC migration were observed with ATRA concentrations as low as 0.2 μM. DMSO, which is used as vehicle for ATRA and other retinoids, has no effect on PDGF-induced airway SMC migration. This does not appear to be due to the effects of ATRA on cell proliferation, as MTT assay showed that ATRA is not effective in inhibiting PDGF-induced cell proliferation; additionally, migration assay with 4 h of PDGF treatment also exhibits the ability of ATRA to inhibit migratory responses, as monitored using a modified Boyden chamber assay. Thus, although ATRA is ineffective in inhibiting proliferation and inducing apoptosis of airway SMCs, ATRA is an efficient inhibitor of airway SMC migration. Furthermore, using actinomycin D, a general inhibitor of gene transcription, showed that ATRA inhibition of SMC migration does not mediate gene transcriptional events.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:34:27 GMT 2025
Edited
by admin
on Mon Mar 31 17:34:27 GMT 2025
Record UNII
5688UTC01R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RETINOIC ACID
INCI   MI  
INCI  
Preferred Name English
Tretinoin
EP   HSDB   INN   JAN   MART.   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
TRETINOIN [ORANGE BOOK]
Common Name English
ORISTAR RNA
Brand Name English
TRETINOIN [JAN]
Common Name English
RETINOIC ACID [MI]
Common Name English
RETIN-A
Brand Name English
TRETINOIN [USP-RS]
Common Name English
TRI-LUMA COMPONENT TRETINOIN
Common Name English
SOLAGE COMPONENT TRETINOIN
Common Name English
VESANOID
Brand Name English
TRETINOIN [VANDF]
Common Name English
RETIN A
Brand Name English
TRETINOIN [USAN]
Common Name English
ISOTRETINOIN IMPURITY A [EP IMPURITY]
Common Name English
TWYNEO COMPONENT TRETINOIN
Brand Name English
TRETINOIN [MART.]
Common Name English
TRETINOIN [HSDB]
Common Name English
NSC-122758
Code English
KERLOCAL
Brand Name English
TRETINOIN [USP MONOGRAPH]
Common Name English
ZIANA COMPONENT TRETINOIN
Common Name English
tretinoin [INN]
Common Name English
TRETINOIN [EP MONOGRAPH]
Common Name English
RENOVA
Brand Name English
ATRA
Common Name English
Tretinoin [WHO-DD]
Common Name English
ALTRENO
Brand Name English
EUDYNA
Brand Name English
ABEREL
Brand Name English
all-trans-Retinoic acid
Common Name English
ALL-TRANS RETINOIC ACID
Common Name English
AVITA
Brand Name English
VELTIN COMPONENT TRETINOIN
Brand Name English
Classification Tree Code System Code
NDF-RT N0000007700
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
NDF-RT N0000175607
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
NCI_THESAURUS C68299
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
WHO-VATC QL01XX14
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
FDA ORPHAN DRUG 71692
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
NCI_THESAURUS C804
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
FDA ORPHAN DRUG 5785
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
FDA ORPHAN DRUG 165802
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
LOINC 87673-0
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
WHO-VATC QD10AD51
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
FDA ORPHAN DRUG 50990
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
WHO-ATC D10AD51
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
NDF-RT N0000007700
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
NDF-RT N0000007700
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
WHO-ATC D10AD01
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
WHO-VATC QD10AD01
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
WHO-ATC L01XX14
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
NDF-RT N0000007700
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
NDF-RT N0000007700
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
LIVERTOX 993
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
Code System Code Type Description
ChEMBL
CHEMBL38
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
PRIMARY
DRUG CENTRAL
2722
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
PRIMARY
MERCK INDEX
m9558
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
PRIMARY Merck Index
INN
2875
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
PRIMARY
NSC
122758
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
PRIMARY
CHEBI
15367
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
PRIMARY
PUBCHEM
444795
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
PRIMARY
FDA UNII
5688UTC01R
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
PRIMARY
RXCUI
221175
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
ALTERNATIVE
NCI_THESAURUS
C900
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
PRIMARY
WIKIPEDIA
TRETINOIN
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
PRIMARY
RXCUI
10753
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
PRIMARY
DRUG BANK
DB00755
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
PRIMARY
RS_ITEM_NUM
1674004
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
PRIMARY
SMS_ID
100000092588
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
PRIMARY
LACTMED
Tretinoin
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
PRIMARY
CAS
302-79-4
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
PRIMARY
DAILYMED
5688UTC01R
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
PRIMARY
IUPHAR
2644
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
PRIMARY
HSDB
2169
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
PRIMARY
EVMPD
SUB11246MIG
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
PRIMARY
EPA CompTox
DTXSID7021239
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
PRIMARY
ECHA (EC/EINECS)
206-129-0
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
PRIMARY
MESH
D014212
Created by admin on Mon Mar 31 17:34:27 GMT 2025 , Edited by admin on Mon Mar 31 17:34:27 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> AGONIST
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
Binding Assay
IC50
Related Record Type Details
METABOLITE -> PARENT
PARENT -> METABOLITE
Mediator Substance AOX1
METABOLITE -> PARENT
METABOLITE -> PARENT
MAJOR
PLASMA
METABOLITE -> PARENT
MAJOR
PLASMA
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY